此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项在晚期转移性乳腺癌患者中了解名为 ARV-471 (PF-07850327) 的新药的研究。 (VERITAC-2)

2026年11月16日 更新者:Pfizer

ARV-471 (PF-07850327) VS 氟维司群在雌激素受体阳性、HER2 阴性的晚期乳腺癌患者中进行的 ARV-471 (PF-07850327) 随机、开放标签、多中心试验-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

研究概览

地位

主动,不招人

详细说明

The purpose of this study is to learn about the safety and effects of the study medicine ARV-471 (PF-07850327, vepdegestrant) compared to fulvestrant (FUL) in participants with advanced breast cancer. Advanced breast cancer is difficult to cure or control with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body, i.e. bones, lungs, brain, or liver. FUL is a medicine already used for treatment of breast cancer while ARV-471 is a new medicine.

This study is seeking participants with breast cancer who:

  • have cancer that has come back in the place where it started or spread to nearby tissue, lymph nodes, or distant parts of the body.
  • cannot be fully cured by surgery or radiation therapy. Radiation therapy is the use of high-energy radiation such as x-rays, gamma rays and other sources to kill cancer cells and shrink tumors.
  • respond to hormonal or endocrine therapy (which target hormones and/or activity of hormone receptors) such as tamoxifen or aromatase inhibitors (this is called estrogen receptor positive disease)
  • have received one line of CDK4/6 inhibitor therapy (for example palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy (for example letrozole) for advanced cancer.
  • are allowed up to one other endocrine therapy (for example exemestane) for advanced cancer.

Half of the participants will be given ARV-471 while the other half of the participants will be given FUL.

Participants who get ARV-471 will take ARV-471 by mouth with food, one time a day. During the first treatment cycle participants who will get FUL will be given FUL by shots into the muscles on Day 1 and again 2 weeks later. After the first month, FUL shots will be given on the first day of each new treatment cycle. One treatment cycle is 28 days.

Participants will receive the study medicine until their breast cancer worsens or side effects become too severe. Participants will have visits at the study clinic about every 4 weeks.

研究类型

介入性

注册 (实际的)

624

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Luoyang、中国、471003
        • The First Affiliated Hospital of Henan University of Science &Technology
      • Zhengzhou、中国、450008
        • Henan Cancer Hospital
    • Anhui
      • Hefei、Anhui、中国、230001
        • Anhui Provincial Hospital
      • Hefei、Anhui、中国、230031
        • Anhui Provincial Cancer Hospital
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100021
        • Cancer Hospital Chinese Academy of Medical Science
      • Beijing、Beijing Municipality、中国、100005
        • Beijing Hospital
    • Fujian
      • Fuzhou Fujian、Fujian、中国、350001
        • Fujian Medical University Union Hospital
    • Guangdong
      • Foshan、Guangdong、中国、528041
        • The First People's Hospital of Foshan
      • Guangzhou、Guangdong、中国、510060
        • Sun Yat-sen University Cancer Center
      • Guangzhou、Guangdong、中国、510555
        • Sun Yat-sen University Cancer Center
    • Guangxi
      • Nanning、Guangxi、中国、530201
        • Guangxi Medical University Affiliated Tumor Hospital
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150081
        • Harbin Medical University Cancer Hospital
    • Henan
      • Luoyang、Henan、中国、471003
        • The First Affiliated Hospital of Henan University of Science &Technology
    • Hubei
      • Wuhan、Hubei、中国、430079
        • Hubei Cancer Hospital
      • Wuhan、Hubei、中国、430022
        • Wuhan Union Hospital Cancer Center
      • Wuhan、Hubei、中国、430040
        • Jinyinhu Branch of Tongji Medical College Affiliated Union Hospital, Huazhong University of Science
      • Wuhan、Hubei、中国、430022
        • Union Hospital Tongji Medical College Huazhong University of Science and Technology
    • Jiangsu
      • Nanjing、Jiangsu、中国、210031
        • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School
    • Jiangxi
      • Nanchang、Jiangxi、中国、330006
        • The First Affiliated Hospital of Nanchang University
      • Nanchang、Jiangxi、中国、330009
        • Nanchang People's Hospital
    • Jilin
      • Changchun、Jilin、中国、130021
        • The First Hospital of Jilin University
    • Liaoning
      • Dalian、Liaoning、中国、116023
        • The 2nd Affiliated Hospital of Dalian Medical University
      • Shenyang、Liaoning、中国、110001
        • The First Hospital of China Medical University
      • Shenyang、Liaoning、中国、110042
        • Liaoning Cancer Hospital
    • Shaanxi
      • Xi'an、Shaanxi、中国、710061
        • The First Affiliated Hospital of Xi'an Jiaotong University
      • Xi'an、Shaanxi、中国、710004
        • The Second Affiliated Hospital of Xi'an Jiaotong University
    • Shandong
      • Jinan、Shandong、中国、250117
        • Shandong Cancer Hospital
    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • Fudan University Shanghai Cancer Center
      • Shanghai、Shanghai Municipality、中国、200025
        • Ruijin Hospital Shanghai Jiaotong University School of Medicine
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300060
        • Tianjin Medical University Cancer Institute & Hospital
    • Yunnan
      • Kunming、Yunnan、中国、650118
        • Yunnan Province Cancer Hospital
    • Zhejiang
      • Hangzhou、Zhejiang、中国、310022
        • Zhejiang Cancer Hospital
      • Hangzhou、Zhejiang、中国、310016
        • Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
      • Hangzhou、Zhejiang、中国、310052
        • The Second Affiliated hospital of Zhejiang University school of medicine
    • Central District
      • Petah Tikva、Central District、以色列、4941492
        • Rabin Medical Center
      • Rehovot、Central District、以色列、7610001
        • Kaplan Medical Center
      • Burgas、保加利亚、8000
        • Complex Oncology Center - Burgas
      • Plovdiv、保加利亚、4004
        • Complex Oncology Center - Plovdiv EOOD
    • Alberta
      • Edmonton、Alberta、加拿大、T6G 1Z2
        • Cross Cancer Institute
    • British Columbia
      • Surrey、British Columbia、加拿大、V3V 1Z2
        • BC Cancer Surrey
    • New Brunswick
      • Moncton、New Brunswick、加拿大、E1C 6Z8
        • The Moncton Hospital
    • Ontario
      • Kitchener、Ontario、加拿大、N2G 1G3
        • Waterloo Regional Health Network
      • Toronto、Ontario、加拿大、M4N 3M5
        • Sunnybrook Research Institute
      • Toronto、Ontario、加拿大、M5B 1W8
        • Unity Health Toronto, St. Michael's Hospital
    • Quebec
      • Saint-Jérôme、Quebec、加拿大、J7Y 0L1
        • Centre de Services Ambulatoires de St-Jerome
      • Saint-Jérôme、Quebec、加拿大、J7Z 2V4
        • Unité de Recherche Clinique du CISSS des Laurentides
      • Budapest、匈牙利、1145
        • Budapesti Uzsoki Utcai Kórház
    • Győr-Moson-Sopron
      • Győr、Győr-Moson-Sopron、匈牙利、9024
        • Petz Aladar Egyetemi Oktato Korhaz
    • Free State
      • Bloemfontein、Free State、南非、9301
        • Iatros International
    • Gauteng
      • Johannesburg、Gauteng、南非、2193
        • Wits Clinical Research
      • Johannesburg、Gauteng、南非、2193
        • Charlotte Maxeke Johannesburg Academic Hospital
      • Johannesburg、Gauteng、南非、2193
        • WCR Office
    • Haryana
      • Gurgaon、Haryana、印度、122001
        • Artemis hospital
    • Maharashtra
      • Mumbai、Maharashtra、印度、400012
        • Tata Memorial Hospital
      • Nashik、Maharashtra、印度、422002
        • HCG Manavata Cancer Centre
      • Nashik、Maharashtra、印度、422009
        • Apex Wellness Hospital
      • Thane、Maharashtra、印度、401107
        • Bhakti Vedanta Hospital and Research Institute
    • National Capital Territory of Delhi
      • New Delhi、National Capital Territory of Delhi、印度、110085
        • Rajiv Gandhi Cancer Institute And Research Centre
      • New Delhi、National Capital Territory of Delhi、印度、110075
        • Venkateshwar Hospital
    • West Bengal
      • Kolkata、West Bengal、印度、700020
        • Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital
      • Kaohsiung City、台湾、80756
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung、台湾、40447
        • China Medical University Hospital
      • Tainan、台湾、704
        • National Cheng Kung University Hospital
      • Taipei、台湾、10002
        • National Taiwan University Hospital
      • Taipei、台湾、11217
        • Taipei Veterans General Hospital
      • Taipei、台湾、10449
        • Mackay Memorial Hospital
      • Taipei、台湾、112
        • Koo Foundation Sun Yat-Sen Cancer Center
      • Taipei、台湾、116
        • Taipei Municipal Wan Fang Hospital
      • Taoyuan、台湾、333
        • Chang Gung Medical Foundation-Linkou Branch
    • Kaohsiung
      • Kaohsiung Niao Sung Dist、Kaohsiung、台湾、83301
        • Chang Gung Memorial Hospital at Kaohsiung
    • Tainan
      • Tainan、Tainan、台湾、71004
        • Chi Mei Medical Center
      • Tainan、Tainan、台湾、73657
        • Chi Mei Hospital - Liouying Branch
      • Adana、土耳其(türkiye)、01140
        • Adana Medical Park Seyhan Hastanesi
      • Adana、土耳其(türkiye)、01370
        • Adana Sehir Egitim ve Arastirma Hastanesi
      • Ankara、土耳其(türkiye)、06520
        • Memorial Ankara Hastanesi
      • Ankara、土耳其(türkiye)、06010
        • Gulhane Egitim Arastirma Hastanesi
      • Ankara、土耳其(türkiye)、06800
        • Ankara Bilkent Şehir Hastanesi
      • Antalya、土耳其(türkiye)、07059
        • Akdeniz Universitesi Hastanesi
      • Edirne、土耳其(türkiye)、22030
        • Trakya University Medical Faculty Hospital
      • Samsun、土耳其(türkiye)、55200
        • Samsun Medical Park Hastanesi
    • Ankara
      • Altindağ、Ankara、土耳其(türkiye)、06230
        • Hacettepe Universite Hastaneleri
    • İ̇stanbul
      • Istanbul、İ̇stanbul、土耳其(türkiye)、34722
        • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
      • Istanbul、İ̇stanbul、土耳其(türkiye)、34752
        • Acibadem Altunizade Hospital
    • İ̇zmir
      • Izmir、İ̇zmir、土耳其(türkiye)、35575
        • I.E.U. Medical Point Hastanesi
      • Oaxaca City、墨西哥、68020
        • Centro de Investigacion Clinica de Oaxaca
    • Jalisco
      • Guadajalara、Jalisco、墨西哥、44600
        • Boca Clinical Trials Mexico S.C.
    • Mexico City
      • Cuauhtémoc、Mexico City、墨西哥、06100
        • Cryptex Investigación Clínica S.A. de C.V.
      • Salzburg、奥地利、5020
        • Uniklinikum Salzburg
    • Styria
      • Graz、Styria、奥地利、8036
        • Medizinische Universität Graz
      • São Paulo、巴西、04014-002
        • IBCC - Núcleo de Pesquisa e Ensino
      • São Paulo、巴西、03102002
        • IBCC - Instituto Brasileiro de Controle do Câncer
    • Espírito Santo
      • Vitória、Espírito Santo、巴西、29043-260
        • Hospital Santa Rita de Cassia
    • Rio Grande do Sul
      • Ijuí、Rio Grande do Sul、巴西、98700-000
        • ONCOSITE - Centro de Pesquisa Clinica em Oncologia
      • Porto Alegre、Rio Grande do Sul、巴西、90035-001
        • Hospital Moinhos de Vento
      • Porto Alegre、Rio Grande do Sul、巴西、90880-480
        • Hospital Mae de Deus
      • Porto Alegre、Rio Grande do Sul、巴西、90850-170
        • Centro de Pesquisa Clínica - Área Administrativa
      • Porto Alegre、Rio Grande do Sul、巴西、90610-000
        • Hospital São Lucas da PUCRS
      • Porto Alegre、Rio Grande do Sul、巴西、90110-270
        • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa
    • Santa Catarina
      • Lages、Santa Catarina、巴西、88501001
        • ANIMI - Unidade de Tratamento Oncologico
    • São Paulo
      • Santo André、São Paulo、巴西、09060-650
        • Faculdade de Medicina do ABC
      • São Paulo、São Paulo、巴西、01509-010
        • A. C. Camargo Cancer Center
    • Achaḯa
      • Pátrai、Achaḯa、希腊、26504
        • University Hospital of Patras
    • Attikí
      • Athens、Attikí、希腊、115 28
        • Alexandra General Hospital of Athens
      • Chaidari/Athens、Attikí、希腊、12462
        • Attikon General University Hospital
    • Irakleío
      • Heraklion、Irakleío、希腊、715 00
        • University General Hospital of Heraklion
    • Thessalía
      • Larissa、Thessalía、希腊、41110
        • University General Hospital of Larissa
      • Berlin、德国、10707
        • Onkologische Schwerpunktpraxis Kurfuerstendamm
      • Milan、意大利、20141
        • Istituto Europeo di Oncologia IRCCS
      • Padova、意大利、35128
        • Istituto Oncologico Veneto IRCCS
      • Province of Macerata、意大利、62100
        • Ospedale Generale Provinciale Macerata
    • Campania
      • Naples、Campania、意大利、80131
        • Istituto Nazionale Tumori IRCCS Fondazione Pascale
    • Catania
      • Misterbianco、Catania、意大利、95045
        • Humanitas Istituto Clinico Catanese
    • Emilia-Romagna
      • Bologna、Emilia-Romagna、意大利、40138
        • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola
    • Ferrara
      • Cona、Ferrara、意大利、44124
        • Azienda Ospedaliero Universitaria di Ferrara
    • Lazio
      • Rome、Lazio、意大利、00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
    • Lombardy
      • Monza、Lombardy、意大利、20900
        • Fondazione IRCCS San Gerardo dei Tintori
    • The Marches
      • Ancona、The Marches、意大利、60126
        • Azienda Ospedaliero Universitaria delle Marche
    • Tuscany
      • Pisa、Tuscany、意大利、56126
        • Azienda Ospedaliero Universitaria Pisana
      • Prague、捷克语、100 34
        • Fakultni nemocnice Kralovske Vinohrady
    • Brno-město
      • Brno、Brno-město、捷克语、625 00
        • Fakultní nemocnice Brno Bohunice
    • Praha 4
      • Prague、Praha 4、捷克语、14059
        • Fakultni Thomayerova nemocnice
      • Bratislava、斯洛伐克、833 10
        • Narodny onkologicky ustav
      • Bratislava、斯洛伐克、812 50
        • Onkologicky ustav sv. Alzbety, s.r.o.
      • Košice、斯洛伐克、04191
        • Vychodoslovensky onkologicky ustav, a.s.
      • Partizánske、斯洛伐克、95801
        • Nemocnica na okraji mesta n o
      • Trnava、斯洛伐克、917 75
        • Fakultna nemocnica Trnava
      • Fukuoka、日本、811-1395
        • National Hospital Organization Kyushu Cancer Center
      • Kagoshima、日本、892-0833
        • Sagara Hospital
      • Okayama、日本、700-8558
        • Okayama University Hospital
    • Aichi-ken
      • Nagoya、Aichi-ken、日本、466-8560
        • Nagoya University Hospital
      • Nagoya、Aichi-ken、日本、467-8602
        • Nagoya City University Hospital
      • Nagoya、Aichi-ken、日本、464-8681
        • Aichi Cancer Center Hospital
    • Chiba
      • Chiba、Chiba、日本、260-8717
        • Chiba cancer center
      • Kashiwa、Chiba、日本、277-8577
        • National Cancer Center Hospital East
    • Hokkaido
      • Sapporo、Hokkaido、日本、003-0804
        • National Hospital Organization Hokkaido Cancer Center
    • Kanagawa
      • Yokohama、Kanagawa、日本、2418515
        • Kanagawa cancer center
    • Osaka
      • Suita、Osaka、日本、565-0871
        • Osaka University Hospital
    • Saitama
      • Ina-machi、Saitama、日本、362-0806
        • Saitama Prefectural Cancer Center
    • Tokyo
      • Bunkyo-ku、Tokyo、日本、113-8431
        • Juntendo University Hospital
      • Bunkyo-ku、Tokyo、日本、113-8677
        • Tokyo Metropolitan Komagome Hospital, Department of Breast Surgery
      • Koto、Tokyo、日本、135-8550
        • Japanese Foundation for Cancer Research
      • Koto-ku、Tokyo、日本、135-8550
        • Cancer Institute Hospital of JFCR
      • Shinjuku、Tokyo、日本、162-8655
        • National Center for Global Health and Medicine
      • Shinjuku-ku、Tokyo、日本、162-8655
        • Center Hospital of the National Center for Global Health and Medicine
      • Liège、比利时、4000
        • Clinical Chc Montlégia
    • Antwerpen
      • Edegem、Antwerpen、比利时、2650
        • Antwerp University Hospital
    • Bruxelles-capitale, Région de
      • Woluwe-Saint-Lambert、Bruxelles-capitale, Région de、比利时、1200
        • Cliniques universitaires Saint-Luc
    • Hainaut
      • Gilly、Hainaut、比利时、6060
        • Grand Hôpital de Charleroi
    • Vlaams-brabant
      • Leuven、Vlaams-brabant、比利时、3000
        • UZ Leuven
    • Côte-d'or
      • Dijon、Côte-d'or、法国、21079
        • Centre Georges François Leclerc
    • Languedoc-roussillon
      • Montpellier、Languedoc-roussillon、法国、34070
        • Centre de Cancérologie du Grand Montpellier
    • Loire-atlantique
      • Saint-Herblain、Loire-atlantique、法国、44805
        • Institut de Cancérologie de l'Ouest
    • Maine-et-loire
      • Angers、Maine-et-loire、法国、49055
        • Institut de Cancérologie de l'Ouest
    • Puy-de-dôme
      • Clermont-Ferrand、Puy-de-dôme、法国、63011
        • Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne
    • Vaucluse
      • Avignon、Vaucluse、法国、84918
        • Sainte Catherine Institut du Cancer Avignon Provence
    • Vienne
      • Poitiers、Vienne、法国、86021
        • Centre Hospitalier Universitaire de Poitiers
    • Île-de-France Region
      • Créteil、Île-de-France Region、法国、94010
        • Henri Mondor Hospital
    • Lesser Poland Voivodeship
      • Krakow、Lesser Poland Voivodeship、波兰、30-348
        • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
      • Krakow、Lesser Poland Voivodeship、波兰、31-501
        • SP ZOZ Szpital Uniwersytecki w Krakowie
    • Masovian Voivodeship
      • Warsaw、Masovian Voivodeship、波兰、02-781
        • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
    • Pomeranian Voivodeship
      • Gdansk、Pomeranian Voivodeship、波兰、80-219
        • COPERNICUS PL, Wojewodzkie Centrum Onkologii
    • Łódź Voivodeship
      • Lodz、Łódź Voivodeship、波兰、90-338
        • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna
      • Rio Piedras、波多黎各、00935
        • Pan American Center for Oncology Trials, LLC
      • Rio Piedras、波多黎各、00935
        • Hospital Oncológico Dr. Isaac González-Martinez
      • San Juan、波多黎各、00927
        • FDI Clinical Research
    • Puerto RICO
      • Hato Rey、Puerto RICO、波多黎各、00917
        • Puerto Rico Medical Research Center
    • New South Wales
      • Coffs Harbour、New South Wales、澳大利亚、2450
        • Coffs Harbour Health Campus
    • Queensland
      • Birtinya、Queensland、澳大利亚、4575
        • Sunshine Coast University Private Hospital
      • Woolloongabba、Queensland、澳大利亚、4102
        • Princess Alexandra Hospital
    • South Australia
      • Kurralta Park、South Australia、澳大利亚、5037
        • ICON Cancer Centre - Kurralta Park
    • Tasmania
      • Hobart、Tasmania、澳大利亚、7000
        • Icon Cancer Centre Hobart
    • Victoria
      • Brighton、Victoria、澳大利亚、3186
        • Cabrini Hospital -Brighton
      • Geelong、Victoria、澳大利亚、3220
        • Barwon Health
      • Malvern、Victoria、澳大利亚、3144
        • Cabrini Hospital - Malvern
    • Stockholms LÄN [se-01]
      • Stockholm、Stockholms LÄN [se-01]、瑞典、11883
        • Södersjukhuset
    • Canton of Aargau
      • Aarau、Canton of Aargau、瑞士、5000
        • Tumor Zentrum Aarau
    • Thurgau
      • Frauenfeld、Thurgau、瑞士、8501
        • Kantonsspital Frauenfeld - Spital Thurgau AG
      • Münsterlingen、Thurgau、瑞士、CH8596
        • Kantonsspital Münsterlingen - Spital Thurgau AG
    • California
      • Encinitas、California、美国、92024
        • California Cancer Associates for Research and Excellence, Inc. (cCARE)
      • Fountain Valley、California、美国、92708
        • Orange Coast Memorial Medical Center
      • Fresno、California、美国、93720
        • California Cancer Associates for Research and Excellence
      • Napa、California、美国、94558
        • Providence Queen of the Valley Medical Center
      • San Marcos、California、美国、92069
        • California Cancer Associates for Research and Excellence
      • Sylmar、California、美国、91342
        • Olive View-UCLA Medical Center
    • Connecticut
      • Fairfield、Connecticut、美国、06824
        • Smilow Cancer Hospital Care Center at Fairfield
      • New Haven、Connecticut、美国、06510
        • Yale-New Haven Hospital
      • New Haven、Connecticut、美国、06510
        • Smilow Cancer Hospital at Yale-New Haven
      • New Haven、Connecticut、美国、06511
        • Smilow Cancer Hospital/Phase 1 Clinic
      • North Haven、Connecticut、美国、06473
        • Smilow Cancer Hospital Care Center at North Haven
      • Trumbull、Connecticut、美国、06611
        • Smilow Cancer Hospital Care Center at Trumbull
    • Florida
      • Bonita Springs、Florida、美国、34135
        • Florida Cancer Specialists BON
      • Bradenton、Florida、美国、34211
        • Florida Cancer Specialists LRS
      • Cape Coral、Florida、美国、33909
        • Florida Cancer Specialists NFM
      • Clearwater、Florida、美国、33761
        • Florida Cancer Specialists
      • Clearwater、Florida、美国、33756
        • Morton Plant Hospital - BayCare Health System
      • Daytona Beach、Florida、美国、32117
        • Florida Cancer Specialists
      • Fleming Island、Florida、美国、32003
        • Florida Cancer Specialist
      • Fort Myers、Florida、美国、33901
        • Florida Cancer Specialists - South
      • Fort Myers、Florida、美国、33905
        • Florida Cancer Specialists COL
      • Fort Myers、Florida、美国、33908
        • Florida Cancer Specialists GLO
      • Gainesville、Florida、美国、32605
        • Florida Cancer Specialists
      • Lakeland、Florida、美国、33805
        • Lakeland Regional Cancer Center
      • Largo、Florida、美国、33770
        • Florida Cancer Specialists
      • Lecanto、Florida、美国、34461
        • Florida Cancer Specialists
      • N. Venice、Florida、美国、34275
        • Florida Cancer Specialist And Research Institute
      • Naples、Florida、美国、34102
        • Florida Cancer Specialists NGD
      • North Port、Florida、美国、34286
        • Florida Cnacer Specialists
      • Ocala、Florida、美国、34474
        • Florida Cancer Specialists
      • Orlando、Florida、美国、32806
        • Florida Cancer Specialists
      • Port Charlotte、Florida、美国、33980
        • Florida Cancer Specialists PCH
      • Sarasota、Florida、美国、34236
        • Florida Cancer Specialists SAD
      • St. Petersburg、Florida、美国、33701
        • Florida Cancer Specialists
      • Tampa、Florida、美国、33607
        • Florida Cancer Specialists
      • The Villages、Florida、美国、32159
        • Florida Cancer Specialists
      • Trinity、Florida、美国、34655
        • Florida Cancer Specialist
      • Wellington、Florida、美国、33414
        • Florida Cancer Specialists
      • West Palm Beach、Florida、美国、33401
        • Florida Cancer Specialists
      • Winter Park、Florida、美国、32789
        • Florida Cancer Specialists
    • Illinois
      • Hinsdale、Illinois、美国、60521
        • Hope and Healing Cancer Services
    • Kansas
      • Overland Park、Kansas、美国、66213
        • Saint Luke's South Hospital
    • Kentucky
      • Louisville、Kentucky、美国、40202
        • Norton Hospital
      • Louisville、Kentucky、美国、40241
        • Norton Brownsboro Hospital
      • Louisville、Kentucky、美国、40207
        • Norton Cancer Institute, St Matthews Campus
      • Louisville、Kentucky、美国、40241
        • Norton Cancer Institute, Brownsboro Hospital Campus
      • Louisville、Kentucky、美国、40202
        • Norton Cancer Institute, Downtown
      • Louisville、Kentucky、美国、40202
        • Norton Cancer Institute - Downtown
      • Louisville、Kentucky、美国、40207
        • Norton Women's & Children's Hospital
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • University Medical Center New Orleans
      • Shreveport、Louisiana、美国、71103
        • Louisiana State University Health Sciences Shreveport
    • Mississippi
      • Hattiesburg、Mississippi、美国、39401
        • Hattiesburg Clinic Hematology/Oncology
    • Missouri
      • Ballwin、Missouri、美国、63011
        • Mercy Clinic Oncology and Hematology
      • Kansas City、Missouri、美国、64111
        • Saint Luke's Hospital of Kansas City
      • Kansas City、Missouri、美国、64111
        • Saint Luke's Cancer Institute
      • Lee's Summit、Missouri、美国、64086
        • Saint Luke's East Hospital
      • St Louis、Missouri、美国、63141
        • Mercy Research - David C. Pratt Cancer Center
    • New Hampshire
      • Lebanon、New Hampshire、美国、03756
        • Dartmouth-Hitchcock Medical Center
    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • MSK Basking Ridge
      • Middletown、New Jersey、美国、07748
        • MSK Monmouth
      • Montvale、New Jersey、美国、07645
        • Memorial Sloan Kettering - Bergen
    • New York
      • Camillus、New York、美国、13031
        • Hematology Oncology Associates of CNY
      • Commack、New York、美国、11725
        • MSK Commack
      • East Syracuse、New York、美国、13057
        • Hematology-Oncology Associates of Central New York, PC
      • Harrison、New York、美国、10604
        • MSK Westchester
      • Lake Success、New York、美国、11042
        • R.J. Zuckerberg Cancer Center
      • Mount Kisco、New York、美国、10549
        • Northern Westchester Hospital
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center
      • New York、New York、美国、10065
        • MSK Evelyn H. Lauder Breast and Imaging Center
      • Nyack、New York、美国、10960
        • Hematology Oncology Associates of Rockland
      • Sleepy Hollow、New York、美国、10591
        • Phelps Hospital
      • Uniondale、New York、美国、11553
        • MSK Nassau
    • Oklahoma
      • Lawton、Oklahoma、美国、73505
        • Cancer Centers of Southwest Oklahoma
    • Oregon
      • Portland、Oregon、美国、97213
        • Providence Cancer Institute Franz Clinic
      • Portland、Oregon、美国、97213
        • Providence Portland Medical Center
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • University of Virginia Health System
      • Charlottesville、Virginia、美国、22903
        • University of Virginia Cancer Center
      • Charlottesville、Virginia、美国、22911
        • UVA Breast Care Center
      • Mechanicsville、Virginia、美国、23116
        • Bon Secours Memorial Regional Medical Center
      • Midlothian、Virginia、美国、23114
        • Bon Secours St. Francis Medical Center
      • Richmond、Virginia、美国、23226
        • Bon Secours St. Mary's Hospital
    • Washington
      • Aberdeen、Washington、美国、98520
        • Providence Regional Cancer System - Aberdeen
      • Centralia、Washington、美国、98531
        • Providence Regional Cancer System- Centralia
      • Lacey、Washington、美国、98503
        • Providence Regional Cancer System - Lacey
      • Renton、Washington、美国、98055
        • UW Medicine Valley Medical Center
      • Pori、芬兰、28500
        • Satakunnan Keskussairaala
    • Pirkanmaa
      • Tampere、Pirkanmaa、芬兰、33520
        • Tampereen yliopistollinen sairaala
    • Pohjanmaa
      • Vaasa、Pohjanmaa、芬兰、65130
        • Vaasan Keskussairaala
      • Blackburn、英国、BB2 3HH
        • Royal Blackburn Hospital
      • Glasgow、英国、G12 0YN
        • The Beatson West of Scotland Cancer Centre
      • Manchester、英国、M20 4GJ
        • The Christie Hospital NHS Foundation Trust
    • London, CITY of
      • London、London, CITY of、英国、EC1A 7BE
        • St Bartholomew's Hospital
      • Granada、西班牙、18016
        • Hospital Universitario San Cecilio
      • Granada、西班牙、18012
        • Hospital Unviersitario Virgen Nieves
      • Granada、西班牙、18012
        • Hospital Universitario Virgen Nieves
      • Madrid、西班牙、28046
        • Hospital Universitario La Paz
      • Madrid、西班牙、28050
        • Hospital Universitario HM Sanchinarro
      • Manresa、西班牙、8423
        • Althaia, Xarxa Assistencial Universitària de Manresa
      • Seville、西班牙、41009
        • Hospital Universitario Virgen Macarena
      • Valencia、西班牙、46014
        • Hospital General Universitario de Valencia
    • A Coruña [LA Coruña]
      • A Coruña、A Coruña [LA Coruña]、西班牙、15006
        • CHUAC-Hospital Teresa Herrera
    • Alicante
      • Elche、Alicante、西班牙、03203
        • Hospital General Universitario de Elche
    • Barcelona [barcelona]
      • Badalona、Barcelona [barcelona]、西班牙、08916
        • Institut Català d'Oncologia (ICO) - Badalona
      • Barcelona、Barcelona [barcelona]、西班牙、08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona、Barcelona [barcelona]、西班牙、08003
        • Parc de Salut Mar - Hospital del Mar
    • Basque Country
      • Bilbao、Basque Country、西班牙、48013
        • Osi Bilbao-Basurto
    • Catalunya [cataluña]
      • L'Hospitalet de Llobregat、Catalunya [cataluña]、西班牙、08908
        • Institut Català d'Oncologia - L'Hospitalet
    • Gipuzkoa
      • Donostia / San Sebastian、Gipuzkoa、西班牙、20014
        • Hospital Universitario Donostia
    • Lleida [lérida]
      • Lleida、Lleida [lérida]、西班牙、25198
        • Hospital Universitario Arnau de Vilanova de Lleida
    • Madrid, Comunidad de
      • Madrid、Madrid, Comunidad de、西班牙、28041
        • Hospital Universitario 12 de Octubre
    • Málaga
      • Málaga、Málaga、西班牙、29010
        • Hospital Universitario Virgen de la Victoria
    • Tarragona [tarragona]
      • Reus、Tarragona [tarragona]、西班牙、43204
        • Salut Sant Joan de Reus-Baix Camp (Edp)
      • Buenos Aires、阿根廷、1431
        • Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)
      • Buenos Aires、阿根廷、C1426ABP
        • Fundación Respirar
      • Buenos Aires、阿根廷、1426
        • Centro Oncologico Korben
      • Córdoba、阿根廷、X5004FHP
        • Clínica Universitaria Reina Fabiola
    • Buenos Aires
      • Berazategui、Buenos Aires、阿根廷、B1884BBF
        • Centro de Oncología e Investigación de Buenos Aires
      • CABA、Buenos Aires、阿根廷、1417
        • Instituto de Oncología Angel H. Roffo
      • Ciudad Autónoma de Buenos Aires、Buenos Aires、阿根廷、C1023AAB
        • Stat Research S.A.
    • Buenos Aires F.D.
      • Buenos Aires、Buenos Aires F.D.、阿根廷、1113
        • Centro de Investigaciones Medicas y Desarrollo LC
    • Santa Fe Province
      • Rosario、Santa Fe Province、阿根廷、2000
        • Fundacion Estudios Clinicos
      • Rosario、Santa Fe Province、阿根廷、S2000ORE
        • Sanatorio de La Mujer
    • Incheon-gwangyeoksi [incheon]
      • Namdong-gu、Incheon-gwangyeoksi [incheon]、韩国、21565
        • Gachon University Gil Medical Center
    • Kyǒnggi-do
      • Goyang-si、Kyǒnggi-do、韩国、10408
        • National Cancer Center
      • Seongnam、Kyǒnggi-do、韩国、13620
        • Seoul National University Bundang Hospital
      • Suwon、Kyǒnggi-do、韩国、16499
        • Ajou University Hospital
    • Seoul-teukbyeolsi [seoul]
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、03080
        • Seoul National University Hospital
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、05505
        • Asan Medical Center
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、06273
        • Gangnam Severance Hospital, Yonsei University Health System
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、06351
        • Samsung Medical Center
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、06591
        • The Catholic Univ. of Korea Seoul St. Mary's Hospital
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、02841
        • Korea University Anam Hospital
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、03722
        • Severance Hospital, Yonsei University Health System
      • Seoul、Seoul-teukbyeolsi [seoul]、韩国、07985
        • Ewha Womans University Mokdong Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult participants with loco-regional recurrent or metastatic breast disease not amenable to surgical resection or radiation therapy
  • Confirmed diagnosis of ER+/HER2- breast cancer
  • Prior therapies for locoregional recurrent or metastatic disease must fulfill all the following criteria:
  • One line of CDK4/6 inhibitor therapy in combination with endocrine therapy. Only one line of CDK4/6 inhibitor is allowed in any setting.
  • ≤ 1 endocrine therapy in addition to CDK4/6 inhibitor with ET
  • Most recent endocrine treatment duration must have been given for ≥6 months prior to disease progression. This may be the endocrine treatment component of the CDK4/6 inhibitor line of therapy.
  • Radiological progression during or after the last line of therapy.
  • Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • Participants should be willing to provide blood and tumor tissue

Exclusion Criteria:

  • Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term
  • Prior treatment with:
  • ARV-471, fulvestrant, elacestrant, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitor for any setting
  • other investigational agents (including novel endocrine therapy any SERDs, SERCAs, CERANs) for any setting
  • prior chemotherapy for advanced/metastatic disease
  • Inadequate liver, kidney and bone marrow function
  • Active brain metastases
  • Participants with significant concomitant illness

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:ARV-471

orally, once daily on a 28-day continuous dosing schedule

其他名称:
  • PF-07850327
有源比较器:氟维司群

intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1- All Randomized Participants
大体时间:From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective progression of disease (PD) per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 millimeters (mm) relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.

From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
PFS by BICR Assessment Per RECIST v1.1-Participants With ESR1 Mutation
大体时间:From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

PFS assessed by BICR was defined as the time from the date of randomization to the date of the first documentation of objective PD per RECIST v1.1, or death due to any cause, whichever occurred first. PD as per RECIST v1.1 was defined as at least a 20% increase in the sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to the timepoint under evaluation), with a minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions or the presence of new lesions. PFS was censored on the date of last adequate disease assessment for those who did not have a PFS event, discontinued the study treatment due to withdrawal of consent prior to an event, started a new anticancer therapy prior to an event, had an event after a gap of 2 or more missing disease assessments, or lost to follow-up. Kaplan-Meier method was used.

From date of randomization to date of first documentation of objective PD or death (any cause) or censoring date, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS)-All Randomized Participants
大体时间:From date of randomization to the date of death due to any cause or censoring date

OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.

From date of randomization to the date of death due to any cause or censoring date
OS-Participants With ESR1 Mutation
大体时间:From date of randomization to the date of death due to any cause or censoring date

OS was defined as the time from date of randomization to date of death due to any cause. In case of no death, OS time would be censored on the date participant was last known to be alive.

From date of randomization to the date of death due to any cause or censoring date
Percentage of Participants With Objective Response (OR) by BICR Assessment- Participants With Measurable Disease at Baseline
大体时间:From randomization until PD, death or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

OR was defined as the best overall response of confirmed complete response (CR) or partial response (PR) by BICR assessment as per RECIST v1.1 criteria. As per RECIST v1.1, CR was defined as complete disappearance of all target lesions, with the exception of nodal disease, complete disappearance of all non-target lesions and no new lesions. All nodes decreased to normal (short axis <10 mm); all target lesions and disease sites were assessed. PR was defined as at least a 30% decrease from baseline in the sum of diameters of all target lesions, non-PD/not evaluated for the non-target lesions and no new lesions. The short diameter was used in the sum for nodal target lesions, while the longest diameter was used in the sum for non-nodal target lesions, all target lesions were assessed.

From randomization until PD, death or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Clinical Benefit Rate (CBR) by BICR Assessment
大体时间:From randomization until PD, death due to any cause or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

CBR: percentage of participants with clinical benefit response. Clinical benefit response: confirmed CR or PR at any time, or stable disease (SD) >=24 weeks per RECIST v1.1. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis <10 mm); all disease sites, all target lesions assessed. PR: >=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions assessed. SD: did not qualify for CR, PR, PD. All target lesions assessed. PD per RECIST v1.1: at least 20% increased sum of diameters of target measurable lesions above nadir (smallest sum observed considering baseline and all assessments prior to timepoint under evaluation), with minimum absolute increase of 5mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.

From randomization until PD, death due to any cause or start of new anticancer therapy, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Duration of Response (DOR) by BICR Assessment
大体时间:From first documentation of objective tumor response until confirmed PD or death, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)

DOR was defined as time from first documentation of objective tumor response (CR or PR) to first documentation of PD, or death due to any cause, whichever occurred first. CR: complete disappearance of all target lesions, of all non-target lesions and no new lesions; except for nodal disease, all nodes decreased to normal (short axis <10 mm); all disease sites, all target lesions assessed. PR: >=30% decrease from baseline in sum of diameters of all target lesions, non-PD/not evaluated for non-target lesions and no new lesions; all target lesions were assessed. The short diameter is used in the sum for nodal target lesions, while longest diameter is used in sum for non-nodal target lesions, all target lesions were assessed. DOR was analyzed in participants with an OR. PD: at least 20% increase in sum of diameters of target measurable lesions above nadir, with minimum absolute increase of 5 mm relative to nadir or unequivocal progression of existing non-target lesions, or new lesions.

From first documentation of objective tumor response until confirmed PD or death, whichever occurred first (up to 18.56 months and 19.38 months of treatment exposure for vepdegestrant and fulvestrant arms respectively)
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs), Treatment Related TEAEs, Grade 3 or 4 and Grade 5 TEAEs as Assessed by NCI CTCAE v5.0
大体时间:From the first dose of study treatment up to 28 days after last dose of study treatment

Adverse event (AE): any untoward medical occurrence in clinical study participant, temporally associated with use of study treatment, whether or not considered related to study treatment. AEs included both SAEs and all other (non-SAEs) AEs. SAE: any untoward medical occurrence, at any dose met one or more of following criteria: death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect or other important medical events. TEAEs: AEs that occur on or after first dose of study treatment up to 28 days after last dose of study treatment. Relatedness to study drug were judged by investigator. As per National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) severity of AEs were graded as following, Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening; urgent treatment indicated, Grade 5: death related to AE.

From the first dose of study treatment up to 28 days after last dose of study treatment
Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Hematology Parameters Assessed by NCI CTCAE v5.0
大体时间:From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)

Hematological parameters including neutrophil count decreased, white blood cell decreased, anemia, platelet count decreased, hemoglobin increased and leukocytosis were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0, severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that fell outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.

From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Number of Participants With Grade Shift From Baseline to Maximum Post-Baseline in Serum Chemistry Laboratory Abnormalities Assessed by NCI CTCAE v5.0
大体时间:From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)

Serum chemistry parameters including alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatinine increased, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypertriglyceridemia, hypoalbuminemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia were assessed. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment. As per NCI CTCAE v5.0 severity was graded as, Grade 1: mild, Grade 2: moderate, Grade 3: severe and Grade 4: life-threatening; urgent treatment indicated. Grade 0: Non-missing laboratory value that falls outside the grading range for the corresponding laboratory parameter. Categories with at least 1 non-zero values showing any shift in Grade from baseline to post-baseline were reported.

From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Number of Participants According to Categorization of Electrocardiogram (ECG) Parameters
大体时间:From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)

Twelve lead ECGs were collected using an automated ECG machine that calculated heart rate and measured corrected QT (QTc interval, QT interval, PR interval and QRS complex). Criteria for heart rate was as follows, <= 50 beats/minute (min), >=100 beats/min, increase from baseline >= 20 beats/min, decrease from baseline >= 20 beats/min. Criteria for PR interval was >= 220 millisecond (msec). Criteria for QRS interval was >= 120 msec. Criteria for QT interval was as follows, <=450 msec, > 450 to <= 480 msec, >480 to <=500 msec, >500 msec, increase from baseline <= 30 msec, increase from baseline > 30 to <= 60 msec. Criteria for QTCF interval was as follows, <=450 msec, > 450 to <= 480 msec, > 480 to <= 500 msec, > 500 msec, increase from baseline <= 30 msec, increase from baseline > 30 to <= 60 msec, increase from baseline > 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.

From baseline up to 28 days after last dose of study treatment (up to 19.56 months and 20.38 months for vepdegestrant and fulvestrant arms respectively)
Number of Participants According to Categorization of QT Interval Corrected Using Fridericia's Formula (QTcF) Results-QTc Substudy Analysis Set
大体时间:Baseline and from the first dose of study treatment up to the end of treatment (EOT) i.e., 28 days after last dose of study treatment (approximately up to 19.56 months)

Criteria for QTcF interval for single beat were as follows, <= 450 msec, > 450 to <= 480 msec, > 480 to <=500 msec, > 500 msec, increase from baseline <= 30 msec, increase from baseline > 30 to <= 60 msec, increase from baseline > 60 msec. Baseline was defined as the last assessment on or prior to the date of the first dose of study treatment.

Baseline and from the first dose of study treatment up to the end of treatment (EOT) i.e., 28 days after last dose of study treatment (approximately up to 19.56 months)
Change From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire (EORTC QLQ-C30) Score
大体时间:From baseline up to 28 days after last dose of study treatment

The EORTC QLQ-C30 contains 30 items and is composed of 5 multi-item functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), 3 multi-item symptom scales (fatigue, pain and nausea/vomiting), 6 single item symptom scales (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial impact), and one global quality of life scale. This questionnaire contained 30 questions organized into 5 multi-item functional scales, 3 multi-item symptom scales, 6 single item symptom scales, and one global quality of life scale. All the scales and single-item measures range in score from 0 to 100. Higher scores on the functional scales represent higher levels of functioning. Higher scores on the global health status/quality of life scale represent higher health status/quality of life. Higher scores on symptom scales/items represent a greater presence of symptoms.

From baseline up to 28 days after last dose of study treatment
Change From Baseline in European Organization for the Research and Treatment of Cancer and Quality of Life Questionnaire-Breast Cancer Specific (EORTC QLQ-BR23) Score
大体时间:From baseline up to 28 days after last dose of study treatment

The EORTC QLQ-BR23 was a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consisted of four functional scales (body image, sexual functioning, sexual enjoyment, future perspective) and four symptom scales (systemic side-effects, breast symptoms, arm symptoms, upset by hair loss). Each item was rated by choosing 1 of 4 possible responses that record the level of intensity (1= not at all, 2= a little, 3= quite a bit, and 4= very much) within each scale. All scores are converted to a 0 to 100 scale. For functional scales, higher scores represent a better level of functioning. For symptom-oriented scales, higher scores represented greater symptom severity.

From baseline up to 28 days after last dose of study treatment
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and Visual Analogue Scale (VAS) Scores
大体时间:From baseline up to 28 days after last dose of study treatment

The EQ-5D-5L was a 5-item participant-completed questionnaire designed to assess health status in terms of a single index value or utility score. There were 2 components, a Health State Profile where participants rated their level of problems (1=none, 2=slight, 3=moderate, 4=severe, 5=extreme/unable) in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), and a visual analogue scale (VAS) in which participants rated their overall health status from 0 (worst imaginable) to 100 (best imaginable). Responses to 5 dimensions comprised health state/ single utility index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with a predefined index value to it. Every health state (coded as combination of responses) had a unique predefined utility index value assigned to it per US value sets, Overall index scores ranged from 0 to 1, with lower scores representing a higher level of dysfunction.

From baseline up to 28 days after last dose of study treatment
Change From Baseline in Pain Severity and Pain Interference as Assessed by Brief Pain Inventory Short Form (BPI-SF) Score
大体时间:From baseline up to 28 days after last dose of study treatment

The BPI-SF consisted of items to measure participant perceptions of pain severity (item 3), assess degree of interference of pain on daily functioning, body diagrams on which participants indicate location of pain, record pain medication usage, VAS assessed degree of pain relief in last 24 hours (item 9a). Items in pain severity scale evaluated pain "at its worst", "at its least", and "on average" over previous 24 hours, as well as "pain now" (at time of assessment). Participants responded on 10- point numerical rating scale, where 0 = "no pain" and 10 = "pain as bad as you can imagine". Pain interference scale asked participants to rate how their pain interferes with "enjoyment of life", "general activity", "walking ability", "mood", "sleep", "normal work" and "relations with other people." Responses for interference scale were also based on 10-points scale, where 0 = "does not interfere" and 10 = "interferes completely". Higher scores=high levels of pain, impact attributed to pain.

From baseline up to 28 days after last dose of study treatment
Plasma Concentration of ARV-471 and Its Epimer ARV-473
大体时间:Anytime between -4 to 0 hours on Day 1 of Cycle 2, Cycle 3, Cycle 5 and Cycle 7 and anytime between 5 to 7 hours on Day 1 of Cycle 2 and Cycle 3

Plasma concentrations of ARV-471 and its epimer ARV-473 were reported in this outcome measure.

Anytime between -4 to 0 hours on Day 1 of Cycle 2, Cycle 3, Cycle 5 and Cycle 7 and anytime between 5 to 7 hours on Day 1 of Cycle 2 and Cycle 3
Change in Plasma Circulating Tumor DNA (ctDNA) From Baseline
大体时间:Baseline and up to EOT

Quantitative change in plasma ctDNA levels from baseline to each protocol specified time point (up to EOT), as assessed using a validated assay.

Baseline and up to EOT

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年3月3日

初级完成 (实际的)

2025年1月31日

研究完成 (估计的)

2028年5月15日

研究注册日期

首次提交

2022年11月16日

首先提交符合 QC 标准的

2022年12月8日

首次发布 (实际的)

2022年12月16日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅